Is Remimazolam a Friend or Foe?

Abstract

Remimazolam besylate is a novel short-acting benzodiazepine that was first approved as a general anesthetic in Japan. Remimazolam was expected to revolutionize general anesthesia with quick recovery due to its metabolism, which is independent of organ function. Although it has been more than two years since remimazolam’s release, anesthesiologists still lack proficiency in its use. Therefore, this article discusses the drawbacks of remimazolam anesthesia in three stages：induction, maintenance, and emergence, based on the author’s personal experience and review of the current literature.